Active ingredientLomitapideCat. No. P-L086-001CAS 182431-12-5Family · Pharmaceutical analytical standards
Lomitapide
An oral inhibitor of the MTP protein, which the liver uses to assemble and release VLDL lipoproteins. Approved in 2012 in the United States and in 2013 in Europe for homozygous familial hypercholesterolaemia, a rare inherited form of very high cholesterol. This family brings together the active ingredient, metabolites, labelled standards and other impurities.
Did you know?The idea came from abetalipoproteinaemia, a rare disease in which the MTP gene does not work and almost no LDL is made: Daniel Rader, at the University of Pennsylvania, proposed mimicking it with a drug.
Go to the active ingredient →Active ingredientLomitapideCat. No. P-L086-001CAS 182431-12-5
Active ingredientLomitapide MesylateCat. No. P-L086-002CAS 202914-84-9
MetaboliteLomitapide Carboxilic Acid MetaboliteCat. No. P-L086-003CAS 252361-04-9
MetaboliteLomitapide Metabolite 1Cat. No. P-L086-004
MetaboliteLomitapide Metabolite 2Cat. No. P-L086-005CAS 791814-98-7
Isotopically labelledLomitapide-d8Cat. No. P-L086-006CAS 2459377-96-7
ImpurityLomitapide Impurity FCat. No. P-L086-007
ImpurityLomitapide M1Cat. No. P-L086-009CAS 182439-41-4
ImpurityLomitapide M1 HydrochlorideCat. No. P-L086-010CAS 1838769-21-3
ImpurityLomitapide M3Cat. No. P-L086-011CAS 182439-11-8
ImpurityLomitapide N-OxideCat. No. P-L086-012CAS 182430-98-4No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.